April 6, 2021 Enzychem Lifesciences Announces Last Patient Enrolled in Stage 2 of Phase 2 Study of EC-18 in Chemoradiation Induced Oral Mucositis Explore further
March 11, 2021 Enzychem Lifesciences Selected to Participate at the 15th New York Health Forum: Investing in Space – Next Frontier of Healthcare Explore further
March 1, 2021 Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18) Explore further
February 8, 2021 Enzychem Lifesciences Announces Poster Presentation At AACR VirtualAnnual Meeting 2021 Explore further
January 26, 2021 Enzychem Lifesciences Receives NASA Grant Funding to Evaluate EC-18 as a Protective Agent for Radiation and Pathogen-Induced Tissue Damage and Inflammation in Space Explore further
